牛牛AI助手已提取核心信息
On February 13, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, issued a shareholder update via press release, detailing significant operational achievements and outlining future milestones. The company, listed on NASDAQ under the symbol TCBP, announced FDA clearance for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML) and a collaboration with Queen Mary University of London to expand their TCB-008 therapy into anti-fungal and anti-bacterial diseases. TC BioPharm also reported an approximate $11.6 million in cost-savings and the successful completion of the ACHIEVE Study safety cohort. Additionally, the company filed a preliminary proxy statement with the SEC on February 9, 2024, seeking shareholder approval for a potential issuance of shares that could exceed 20% of the outstanding shares at a discounted price, in accordance with Nasdaq Marketplace Rule 5635(d). The Board of Directors has not yet determined the terms of any potential financing. The company emphasized its focus on strategic partnerships and budget savings for the year ahead.
On February 13, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, issued a shareholder update via press release, detailing significant operational achievements and outlining future milestones. The company, listed on NASDAQ under the symbol TCBP, announced FDA clearance for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML) and a collaboration with Queen Mary University of London to expand their TCB-008 therapy into anti-fungal and anti-bacterial diseases. TC BioPharm also reported an approximate $11.6 million in cost-savings and the successful completion of the ACHIEVE Study safety cohort. Additionally, the company filed a preliminary proxy statement with the SEC on February 9, 2024, seeking shareholder approval for a potential issuance of shares that could exceed 20% of the outstanding shares at a discounted price, in accordance with Nasdaq Marketplace Rule 5635(d). The Board of Directors has not yet determined the terms of any potential financing. The company emphasized its focus on strategic partnerships and budget savings for the year ahead.
2024年2月13日，处于临床阶段的生物制药公司TC Biopharm（Holdings）PLC通过新闻稿发布了股东最新情况，详细介绍了重大运营成就并概述了未来的里程碑。该公司在纳斯达克上市，股票代码为TCBP，宣布美国食品药品管理局批准一项针对复发/难治性急性髓系白血病（AML）的1B期研究，并与伦敦玛丽皇后大学合作，将其 TCB-008 疗法扩展到抗真菌和抗菌疾病。TC BioPharm还报告说，节省了约1160万美元的成本，并成功完成了ACHIEVE研究安全队列。此外，该公司于2024年2月9日向美国证券交易委员会提交了初步委托书，根据纳斯达克市场规则5635（d），寻求股东批准可能以折扣价发行可能超过已发行股票20％的股票。董事会尚未确定任何潜在融资的条款。该公司强调将重点放在未来一年的战略伙伴关系和预算节省上。
2024年2月13日，处于临床阶段的生物制药公司TC Biopharm（Holdings）PLC通过新闻稿发布了股东最新情况，详细介绍了重大运营成就并概述了未来的里程碑。该公司在纳斯达克上市，股票代码为TCBP，宣布美国食品药品管理局批准一项针对复发/难治性急性髓系白血病（AML）的1B期研究，并与伦敦玛丽皇后大学合作，将其 TCB-008 疗法扩展到抗真菌和抗菌疾病。TC BioPharm还报告说，节省了约1160万美元的成本，并成功完成了ACHIEVE研究安全队列。此外，该公司于2024年2月9日向美国证券交易委员会提交了初步委托书，根据纳斯达克市场规则5635（d），寻求股东批准可能以折扣价发行可能超过已发行股票20％的股票。董事会尚未确定任何潜在融资的条款。该公司强调将重点放在未来一年的战略伙伴关系和预算节省上。
有用
没用